{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:50:10Z","timestamp":1791831010814,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Frantz Viral Therapeutics"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ygyno.2019.12.035","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T08:17:33Z","timestamp":1580199453000},"page":"188-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2\/3 (CIN2\/3)"],"prefix":"10.1016","volume":"157","author":[{"given":"Cornelia L.","family":"Trimble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Levinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonel","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine T.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Shay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Elizabeth","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Frantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Plesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.12.035_bb0005","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: a synthetic analysis","volume":"4","author":"Plummer","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ygyno.2019.12.035_bb0010","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/AOG.0b013e31828caa31","article-title":"Loop electrosurgical excision procedure and the risk for preterm delivery","volume":"121","author":"Heinonen","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1006\/gyno.2000.5952","article-title":"Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence?","volume":"79","author":"Nagai","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0020","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/jmv.25208","article-title":"Factors affecting residual\/recurrent cervical intraepithelial neoplasia after cervical conization with negative margins","volume":"90","author":"Fan","year":"2018","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejogrb.2012.06.026","article-title":"Risk factors for cervical intraepithelial neoplasia recurrence after conization: a 10-year study","volume":"165","author":"Serati","year":"2012","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0030","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1471-0528.2006.01063.x","article-title":"Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation","volume":"113","author":"Verguts","year":"2006","journal-title":"BJOG."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0035","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1016\/j.vaccine.2012.07.056","article-title":"Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States","volume":"30","author":"Chesson","year":"2012","journal-title":"Vaccine."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0040","series-title":"Early Diagnosis and Screening","article-title":"Cervical Cancer","author":"WHO","year":"2019"},{"key":"10.1016\/j.ygyno.2019.12.035_bb0045","unstructured":"World Health Organization. Guidelines for the Treatment of Malaria. Second edition, March 2010. 2nd Edition Ed. Geneva, Switzerland: World Health Organization; 2010."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0050","series-title":"Artemisinin Derivatives: Summary of Nonclinical Safety Data Introductory Remarks","first-page":"2002","author":"World Health Organization","year":"2002"},{"key":"10.1016\/j.ygyno.2019.12.035_bb0055","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2125.2011.04103.x","article-title":"Artesunate\/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects","volume":"73","author":"McGready","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0060","first-page":"21","article-title":"Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen","volume":"56","author":"Lin","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0065","first-page":"767","article-title":"The anti-malarial artesunate is also active against cancer","volume":"18","author":"Efferth","year":"2001","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0070","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1021\/np0104065","article-title":"Deoxyartemisinin derivatives from photooxygenation of anhydrodeoxydihydroartemisinin and their cytotoxic evaluation","volume":"65","author":"Galal","year":"2002","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0075","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cbi.2010.02.002","article-title":"Factors determining sensitivity or resistance of tumor cell lines towards artesunate","volume":"185","author":"Sertel","year":"2010","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ebiom.2014.11.010","article-title":"A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer","volume":"2","author":"Krishna","year":"2015","journal-title":"EBioMedicine."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0085","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-017-4261-1","article-title":"Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33\/2)","volume":"164","author":"von Hagens","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0090","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.phymed.2018.09.178","article-title":"Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33\/2)","volume":"54","author":"von Hagens","year":"2019","journal-title":"Phytomedicine."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0095","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00280-018-3533-8","article-title":"A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies","volume":"81","author":"Deeken","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0100","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1158\/0008-5472.CAN-05-1216","article-title":"Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo","volume":"65","author":"Disbrow","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0105","first-page":"1819","article-title":"Safety and efficacy field study of artesunate for dogs with non-resectable tumours","volume":"33","author":"Rutteman","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0110","unstructured":"Richard Schlegel D-PH, Astrid Baege. Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections. In: Patent US, editor. US2011."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0115","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-8-39","article-title":"Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies","volume":"8","author":"Gomes","year":"2008","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1471-0528.1970.tb03401.x","article-title":"The natural history of cervical carcinoma in situ","volume":"77","author":"Green","year":"1970","journal-title":"J Obstet Gynaecol Br Commonw."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0125","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0130","first-page":"451","article-title":"The invasive potential of carcinoma in situ of the cervix","volume":"64","author":"McIndoe","year":"1984","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0135","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.297.21.2381","article-title":"Rectal administration of artemisinin derivatives for the treatment of malaria","volume":"297","author":"Karunajeewa","year":"2007","journal-title":"JAMA."},{"issue":"13","key":"10.1016\/j.ygyno.2019.12.035_bb0140","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1158\/1078-0432.CCR-04-2599","article-title":"Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype","volume":"11","author":"Trimble","year":"2005","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0145","doi-asserted-by":"crossref","first-page":"221ra13","DOI":"10.1126\/scitranslmed.3007323","article-title":"Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions","volume":"6","author":"Maldonado","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0150","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0155","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1158\/0008-5472.CAN-16-2346","article-title":"Precancer atlas to drive precision prevention trials","volume":"77","author":"Spira","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0160","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1016\/S1470-2045(17)30373-X","article-title":"Genomic approaches to accelerate cancer interception","volume":"18","author":"Beane","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0165","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1101\/gad.314849.118","article-title":"Molecular mechanisms of the preventable causes of cancer in the United States","volume":"32","author":"Golemis","year":"2018","journal-title":"Genes Dev."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0170","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/1940-6207.CAPR-18-0421","article-title":"AACR white paper: shaping the future of cancer prevention \u2014 a roadmap for advancing science and public health","volume":"11","author":"Lippman","year":"2018","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.ygyno.2019.12.035_bb0175","first-page":"207","article-title":"Effect of cervical carcinoma in situ and its management on pregnancy outcome","volume":"93","author":"El-Bastawissi","year":"1999","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2019.12.035_bb0180","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.fertnstert.2014.12.112","article-title":"Loop electrosurgical excision procedure and risk of miscarriage","volume":"103","author":"Ciavattini","year":"2015","journal-title":"Fertil. Steril."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819318657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819318657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:48:40Z","timestamp":1758772120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819318657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0090825819318657"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.035","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2\/3 (CIN2\/3)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}